Gilead Sciences GILD
-
Gilead Sciences Inc.: Strong Growth At A Low Price
By F.A.S.T. Graphs : Gilead Sciences Inc ( GILD ) is an innovative healthcare company with a strong record of historical earnings growth and expectations for above-average growth …
-
New Morningstar Analyst Report - Gilead Sciences
Gilead 's HIV franchise provides ..... Truvada, and Atripla), Gilead 's pipeline needs to ..... poor use of capital. Gilead Sciences develops and markets therapies ..... in Phase III trials. Gilead Sciences ' focus on infectious …
-
Two Positive Advisory Committee Votes, Quad on Track for August Approval as Expected
… FDA has held two meetings, supporting Gilead GILD products. We had expected positive outcomes ..... infected individuals. We think this puts Gilead on track for a June approval of Truvada ..... 13 to 1) in favor of the approval of Gilead 's newest single-tablet regimen, the …
-
New Morningstar Analyst Report - Celgene
… we expect long-term sales to be limited by Revlimid's uptake. Given Revlimid's 95% gross margin and Gilead Sciences ' GILD success with its small-molecule drugs, we see 40%-plus operating margins in Celgene's future. We assume …
-
An FDA report says Gilead's ([[ GILD ]] +2.4%) HIV treatment Truvada is safe and effective in stopping uninfected people from contracting HIV, although the agency is concerned about when and how it ...
An FDA report says Gilead 's ( GILD +2.4% ) HIV treatment Truvada is safe and effective in stopping ..... used. An FDA advisory panel will meet tomorrow to discuss whether Gilead should be allowed to market Truvada as a prophylaxis Post your …
-
Gilead's Hematology Pipeline: Transformative And Under-Appreciated
By Ohad Hammer: Gilead ( GILD ) is garnering a huge amount of attention ..... ignore additional promising assets in Gilead 's pipeline. GS-1101, which started ..... example. I have no intention to downplay Gilead 's HCV pipeline, however, the minimal …
-
Rolling Gilead Protected Covered Call For Additional Potential Profit
… previous article related to Gilead Sciences ( GILD ) posted on April 13, 2012 ..... In the interim, the price of Gilead Sciences stock has increased 12% as ..... additional potential return. In Gilead 's most recent Q1 2012 earnings …
-
Biotech Takeovers: Who's Next On The Block?
… that money to research and development that may not yield results. The reality is that finding biotech takeover candidates isn't that hard. One just needs to look at the hot niches. For example, Gilead Sciences ( GILD ) Complete Story »
-
Finding An Oncology Player That Will Change The Rules Of The Game
… activity, for drugs with the potential to make a big difference. Gilead ( GILD ) shelled out a whopping $11 billion for Pharmasset last year ..... currently in Phase II testing. Following the announcement, Gilead reaffirmed its goal of developing a hepatitis C drug with significant …
-
Gilead Sciences Looks For Hepatitis C Cure
… last wrote about Gilead Sciences ( GILD ), on July 26 ..... factors is driving Gilead profits higher ..... least 2015." [See Gilead Sciences Readies Pipeline ]. Gilead stock that day closed ..... Friday April 27, GILD closed at $52 …